Adeno-associated virus vectors are promising tools in gene therapy for treating cystic fibrosis. By delivering functional copies of the CFTR gene to affected cells, AAV vectors aim to correct the underlying genetic defect. Their ability to infect non-dividing cells and low immunogenicity make them suitable for targeting respiratory tissues. Ongoing research focuses on improving delivery efficiency and overcoming challenges such as vector immunity to enhance therapeutic outcomes for cystic fibrosis patients.
